SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning

PHASE3RecruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

October 10, 2022

Primary Completion Date

October 9, 2030

Study Completion Date

October 9, 2030

Conditions
Heart Failure AcuteVentilator Lung
Interventions
DRUG

SGLT2 inhibitor

Patients with acute decompensated HF will be open-label randomly assigned to be treated with or without SGLT2 inhibitors (either empagliflozin 10 mg once daily or dapagliflozin 10 mg once daily) 3 days before ventilator weaning in a ratio of 2:1. If the patients are allocated to SGLT2i treatment group, they will be further randomized equally to either empagliflozin- or dapagliflozin-treated group

Trial Locations (1)

100

RECRUITING

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER